NCT06890897 Esketamine Combined Pulsed Radiofrequency for Acute/Subacute Zoster-associated Trigeminal Neuralgia
| NCT ID | NCT06890897 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Beijing Tiantan Hospital |
| Condition | Zoster; Herpes, Trigeminal Neuralgia (Etiology) |
| Study Type | INTERVENTIONAL |
| Enrollment | 174 participants |
| Start Date | 2025-04-01 |
| Primary Completion | 2026-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 174 participants in total. It began in 2025-04-01 with a primary completion date of 2026-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To assess the 1-month effects and safety of esketamine combined PRF and standardized treatment to relieve pain in patients with acute/subacute zoster-related trigeminal neuralgia(ZRTN).
Eligibility Criteria
Inclusion Criteria: 1. Age \>18 years; 2. History of HZ within the last three months; 3. Lesions located in the trigeminal nerve or its branches innervated regions； 4. Numeric Rating Scale (NRS) pain score≥4 (NRS, 0 = no pain, 10= worst possible pain) with pharmacotherapy; 5. Planned to perform CT-guided PRF treatment of the Gasserian ganglion . Exclusion Criteria: 1. Obstructive sleep apnoea syndrome; 2. Those who receive other invasive treatments, such as spinal cord stimulation; 3. A history of systemic immune diseases, organ transplantation, or cancers; 4. A history of severe cardiopulmonary, hepatic or renal dysfunction; 5. A history of schizophrenia, epilepsy, or myasthenia gravis, delirium; 6. Comorbid hyperthyroidism or phaeochromocytoma; 7. Recent history of drug abuse; 8. Having contraindications to esketamine; 9. Communication difficulties. Withdrawal criteria 1. Lost to follow-up during the study; 2. Not perform the planned operation; 3. Receiving other treatment regimes during the study period; 4. Not suitable for continuing the study for emerging severe comorbidities or special physiological changes during the study; 5. Voluntary withdrawal from the study.
Contact & Investigator
Fang Luo, M.D.
PRINCIPAL INVESTIGATOR
Beijing Tiantan Hospital
Frequently Asked Questions
Who can join the NCT06890897 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Zoster; Herpes, Trigeminal Neuralgia (Etiology). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06890897 currently recruiting?
Yes, NCT06890897 is actively recruiting participants. Contact the research team at 13611326978@163.com for enrollment information.
Where is the NCT06890897 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06890897 clinical trial?
NCT06890897 is sponsored by Beijing Tiantan Hospital. The principal investigator is Fang Luo, M.D. at Beijing Tiantan Hospital. The trial plans to enroll 174 participants.